Skip to main content

Table 5 Clinical trials of long-acting erythropoiesis-stimulating agents in peritoneal dialysis patients in Japan

From: 2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease

  Journal title Number of patients Length of study (weeks) Target Hb levels (g/dL) Hb levels at end of treatment (g/dL) Serious adverse events Other side effects (hypertension, etc.)
DA Ther Apher Dial [63] 72 28 Target range:
11–12
New: 10.6 Death: 2 (unrelated) Hypertension: 22
Maintained:
10–13
Switched: 10.5
DA Clin Exp Nephrol [64] 96 28 11–13 11.9±1.2 Death: 0 Hypertension: 22
CERA Jpn Pharmacol Ther [65] 63 48 10–12 SC: 10.88±0.70 Death: 0 Hypertension: 2
IV: 10.78±0.93
CERA Ren Fail [66] 83 48 11–13 11.8±1.5 Death: 1 (unrelated) Hypertension (not provided)
  1. DA darbepoetin alfa, CERA continuous erythropoietin receptor activator, SC subcutaneous administration, IV intravenous administration